Polymer-Free Biolimus A9-Coated Stents in the Treatment of de Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial

JACC: Cardiovascular Interventions

Volumn 9, Issue 1, 2016, Pages 51-64

  Costa, Ricardo A ^a,b   Abizaid, Alexandre ^a,b   Mehran, Roxana ^c   Schofer, Joachim ^d   Schuler, Gerhard C ^e   Hauptmann, Karl E ^f   Magalhães, Marco A ^b   Parise, Helen ^c   Grube, Eberhard ^g  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b Cardiovascular Research Center   (Brazil)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

^e UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^f KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Germany)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

biolimus; carrier free; coronary artery disease; drug coated stent(s); percutaneous coronary intervention; polymer free

Indexed keywords

UMIROLIMUS; CARDIOVASCULAR AGENT; PACLITAXEL; RAPAMYCIN; STAINLESS STEEL;

ADULT; AGED; ANGIOCARDIOGRAPHY; BIOLIMUS ELUTING CORONARY STENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEVICE COMPARISON; DEVICE SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOINTIMA; NEOINTIMAL HYPERPLASIA; OUTCOME ASSESSMENT; PACLITAXEL ELUTING CORONARY STENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; DEVICES; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG ELUTING STENT; GERMANY; KAPLAN MEIER METHOD; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROSTHESIS DESIGN; RISK FACTOR; SINGLE BLIND PROCEDURE; SURFACE PROPERTY; TIME FACTOR;

AGED; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOINTIMA; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; STAINLESS STEEL; SURFACE PROPERTIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84952947036     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.09.008     Document Type: Article

References (32)

1. A. Abizaid, and J.R. Costa Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems Circ Cardiovasc Interv 3 2010 384 393
2. W.J. van der Giessen, A.M. Lincoff, R.S. Schwartz, and et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 1996 1690 1697
3. M. Joner, A.V. Finn, A. Farb, and et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
4. T.F. Luscher, J. Steffel, F.R. Eberli, and et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058
5. G. Nakazawa, E. Ladich, A.V. Finn, and R. Virmani Pathophysiology of vascular healing and stent mediated arterial injury EuroIntervention 4 Suppl C 2008 C7 C10
6. A. Hezi-Yamit, C. Sullivan, J. Wong, and et al. Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design J Biomed Mater Res A 90 2009 133 141
7. S. Windecker, P. Kolh, F. Alfonso, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
8. L. Mauri, D.J. Kereiakes, R.W. Yeh, and et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
9. I.D. Moussa, and A. Colombo Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations Catheter Cardiovasc Interv 74 2009 1047 1054
10. A.J. Lansky, R.A. Costa, G.S. Mintz, and et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial Circulation 109 2004 1948 1954
11. M.W. Krucoff, D.J. Kereiakes, J.L. Petersen, and et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study J Am Coll Cardiol 51 2008 1543 1552
12. J. Mehilli, R.A. Byrne, A. Wieczorek, and et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
13. E.O. Abreu-Silva, R.A. Costa, A. Abizaid, and et al. Late clinical and angiographic follow-up of the new non-polymeric paclitaxel-eluting stent for the treatment of de novo coronary lesions: outcomes of the PAX-B study Rev Bras Cardiol Invasiva 20 2012 146 154
14. M.C. Ostojic, Z. Perisic, D. Sagic, and et al. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study Eur J Clin Pharmacol 67 2011 389 398
15. R.A. Costa, A.J. Lansky, A. Abizaid, and et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions Am J Cardiol 98 2006 443 446
16. S. Windecker, P.W. Serruys, S. Wandel, and et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
17. P.W. Serruys, V. Farooq, B. Kalesan, and et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial J Am Coll Cardiol Intv 6 2013 777 789
18. N. Tada, R. Virmani, G. Grant, and et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model Circ Cardiovasc Interv 3 2010 174 183
19. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
20. G.W. Stone, S.G. Ellis, D.A. Cox, and et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
21. N.G. Kounis, G. Hahalis, and T.C. Theoharides Coronary stents, hypersensitivity reactions, and the Kounis syndrome J Interv Cardiol 20 2007 314 323
22. L.K. Pendyala, J. Li, T. Shinke, and et al. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress J Am Coll Cardiol 2 2009 253 262
23. G. Nakazawa, F. Otsuka, M. Nakano, and et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
24. P.W. Serruys, A.T. Ong, J.J. Piek, and et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial EuroIntervention 1 2005 58 65
25. I.T. Meredith, S. Worthley, R. Whitbourn, and et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial J Am Coll Cardiol Intv 2 2009 977 985
26. S. Hossainy, and S. Prabhu A mathematical model for predicting drug release from a biodurable drug-eluting stent coating J Biomed Mater Res A 87 2008 487 493
27. H. Gada, A.J. Kirtane, W. Newman, and et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 6 2013 1263 1266
28. J.W. Moses, M.B. Leon, J.J. Popma, and et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
29. A. Abizaid, C. Chan, Y.T. Lim, and et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry) Am J Cardiol 98 2006 1028 1032
30. J.M. Lasala, D.A. Cox, D. Dobies, and et al. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry Catheter Cardiovasc Interv 72 2008 433 445
31. G.W. Stone, J.W. Moses, S.G. Ellis, and et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
32. P. Urban, A. Abizaid, B. Chevalier, and et al. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy Am Heart J 165 2013 704 709